SRPT

Sarepta Therapeutics Inc

17.82

Nov 06 • 3:59 PM ET +0.25 (1.42%)

17.82

Aftermarket • 7:48 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Small NASD

Nov 05, 6:43 PMSarepta raises 2026 revenue guidance after Q3 EPS and revenue beat as Elevidys stabilizes, PMO franchise remains strong

Peers: DYN WVE SLDB RGNX EWTX PTCT CAPR RARE PEPG SRRK

| Held by: IJR VTI XBI IWM VB VBK VXF SPSM IWN IBB

Scroll to Statements

Index	RUT
Market Cap	1.91B
Enterprise Value	2.09B
Income	-114.62M
Sales	1.96B
Book/sh	14.26
Cash/sh	8.19
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	835
IPO	Jun 04, 1997

P/E	-
Forward P/E	91.97
PEG	-
P/S	0.98
P/B	1.25
P/C	2.17
P/FCF	11.10
EV/EBITDA	51.02
EV/Sales	1.07
Quick Ratio	2.13
Current Ratio	3.46
Debt/Eq	0.69
LT Debt/Eq	0.59
Option/Short	Yes / Yes

EPS (ttm)	-1.37
EPS next Y	0.19
EPS next Q	-0.31
EPS this Y	137.18%
EPS next Y	-92.69%
EPS next 5Y	-
EPS past 3/5Y	3.92% -0.05%
Sales past 3/5Y	33.06% 32.41%
EPS Y/Y TTM	59.85%
Sales Y/Y TTM	-18.95%
EPS Q/Q	85.03%
Sales Q/Q	-4.51%
Earnings	Nov 05 AMC
EPS/Sales Surpr.	-441.77% 8.28%

Insider Own	4.91%
Insider Trans	0.00%
Inst Own	103.49%
Inst Trans	2.29%
ROA	-3.44%
ROE	-8.05%
ROIC	-4.73%
Gross Margin	54.90%
Oper. Margin	-0.43%
Profit Margin	-5.86%
SMA20	-1.63%
SMA50	-6.84%
SMA200	-4.43%
Trades

Shs Outstand	107.23M
Shs Float	101.97M
Short Float	21.90%
Short Ratio	7.99
Short Interest	22.33M
52W High	24.68 -27.80%
52W Low	14.68 21.39%
Volatility	5.44% 5.39%
ATR (14)	0.98
RSI (14)	46.07
Beta	0.46
Rel Volume	0.93
Avg Volume	2.80M
Volume	2,596,705

Perf Week	-4.30%
Perf Month	-2.14%
Perf Quarter	3.73%
Perf Half Y	-10.70%
Perf YTD	-17.19%
Perf Year	1.02%
Perf 3Y	-77.75%
Perf 5Y	-79.96%
Perf 10Y	-54.55%
Recom	2.75
Target Price	21.59
Prev Close	17.57
Price	17.82
Change %	1.42%

Consensus

Hold

Avg. Price Target

$21.59

Implied Upside

+21.2%

Analysts15incl. previous ratings

Rating Distribution5 Buy · 6 Hold · 4 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Jul 09, 2026	Upgrade	WWolfe Research	Peer Perform → Outperform	$27	+51.5%
Jan 28, 2026	Resumed	BBarclays	Equal Weight	$20	+12.2%
Dec 09, 2025	Initiated	WWedbush	Outperform	$32	+79.6%
Nov 05, 2025	Upgrade	MMizuho	Neutral → Outperform	$26	+45.9%
Sep 22, 2025	Upgrade	BBMO Capital Markets	Market Perform → Outperform	$50	+180.6%
Jul 29, 2025	Upgrade	OOppenheimer	Perform → Outperform	$37	+107.6%
Jul 29, 2025	Upgrade	JJP Morgan	Underweight → Neutral	$24	+34.7%
Jul 29, 2025	Upgrade	BBarclays	Underweight → Equal Weight	$22	+23.5%
Jul 29, 2025	Reiterated	HH.C. Wainwright	Sell	$5	-71.9%
Jul 29, 2025	Initiated	BBernstein	Mkt Perform	$13	-27.0%
Jul 28, 2025	Downgrade	BBarclays	Equal Weight → Underweight	$10	-43.9%
Jul 25, 2025	Downgrade	JJP Morgan	Neutral → Underweight
Jul 24, 2025	Initiated	CCitigroup	Sell	$7	-60.7%
Jul 23, 2025	Downgrade	BBofA Securities	Neutral → Underperform	$10	-43.9%
Jul 22, 2025	Downgrade	BBarclays	Overweight → Equal Weight	$18	+1.0%
Jul 21, 2025	Downgrade	UUBS	Buy → Neutral	$12	-32.7%
Jul 21, 2025	Downgrade	NNeedham	Hold → Underperform
Jul 21, 2025	Downgrade	MMizuho	Outperform → Neutral	$14	-21.4%
Jul 21, 2025	Downgrade	LLeerink Partners	Outperform → Market Perform	$10	-43.9%
Jul 21, 2025	Downgrade	DDeutsche Bank	Buy → Hold	$9	-49.5%

Nov-05-26 09:05PM	Sarepta Misses On Earnings As A Manufacturing Charge Crushes Margins, While PMO Strength Lifts The Revenue Floor And Shifts Focus To Imminent DM1/FSHD Data (Earnings Whispers) -7.48%
05:09PM	Sarepta Therapeutics: Q3 Earnings Snapshot (Associated Press)
Oct-28-26 09:30PM	Sarepta Faces A Revenue Step-Down As Alevitas Recovery Gets Its First Full Test (Earnings Whispers)
Oct-26-26 04:30PM	Sarepta Therapeutics to Present at Upcoming Investor Conferences (Business Wire) +5.06%
Oct-22-26 08:30AM	Sarepta Therapeutics to Announce Third Quarter 2026 Financial Results (Business Wire)
10:44AM	Loading…
Oct-16-26 10:44AM	What Is The Case For Waiting On Moderna Stock? (Trefis)
Oct-14-26 08:30AM	Sarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual Meeting (Business Wire)
Oct-12-26 05:01PM	Where Could Moderna's Next Growth Come From? (Trefis) -5.33%
Sep-30-26 04:30PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
08:30AM	Sarepta Therapeutics Presents New Data at 2026 World Muscle Society Annual Congress Demonstrating Safety and Clinically Meaningful Functional Benefit of ELEVIDYS (delandistrogene moxeparvovec) in Older Ambulatory Patients with Duchenne (Business Wire)
Sep-25-26 08:30AM	Sarepta Therapeutics Announces Presentations at 2026 World Muscle Society Annual Congress (Business Wire)
Sep-24-26 08:30AM	Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 27th Annual Neuromuscular Study Group Scientific Meeting (Business Wire)
Sep-22-26 01:39PM	Was Moderna Stock's Cancer Vaccine Run Visible In Advance? (Trefis)
Sep-08-26 11:04AM	Novartis shares fall as del-desiran flunks Phase 3 myotonic dystrophy trial (Proactive) -6.93%
09:00AM	Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 Academic Year (Business Wire)
04:30PM	Loading…
Aug-31-26 04:30PM	Sarepta Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference (Business Wire)
Aug-27-26 03:00PM	SRPT On Track For Best Week In 5 Months Ahead Of Late-2026 Clinical Data Retail Eyes Monumental Comeback (Stocktwits) +10.95%
Aug-26-26 11:13AM	Moderna Stock Carries A Market Value Its Revenue Does Not Support (Trefis)
Aug-24-26 03:01PM	Moderna Stock Had A Readout Waiting In Plain Sight (Trefis)
10:18AM	Why Regenxbio Halted Its Gene Therapy Trial-and Why the Stock Is Tumbling (Barrons.com)
08:39AM	Regenxbio Stock Sinks 22% Following Surprise Finding in Gene Therapy Trial (Barrons.com)
Aug-20-26 02:21PM	Moderna's Melanoma Result Landed On A Market Positioned The Other Way (Trefis)
Aug-06-26 01:11AM	Sarepta Therapeutics Inc (SRPT) (Q2 2026) Earnings Call Highlights: Strong Profitability and ... (GuruFocus.com) +5.34%
Aug-05-26 05:34PM	Sarepta Therapeutics: Q2 Earnings Snapshot (Associated Press)
04:05PM	Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments (Business Wire)
01:05AM	Arrowhead Pharmaceuticals Inc (ARWR) (Q3 2026) Earnings Call Highlights: Strong Phase III Data ... (GuruFocus.com)
Jul-29-26 05:00PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-28-26 11:35AM	Leadership changes afoot at two CGT biotechs (Pharmaceutical Technology)
Jul-27-26 12:33PM	Morgan Stanley Views Sarepta CEO Transition As A Positive So, Why Is It Cautious On SRPT Stock In The Near Term? (Stocktwits)
08:30AM	Sarepta Therapeutics Appoints Michael Severino, M.D., Chief Executive Officer (Business Wire)
06:16AM	Loading…
06:16AM	Sarepta, in search of a turnaround, taps ex-AbbVie exec Severino as CEO (BioPharma Dive)
Jul-23-26 11:00AM	Is Arrowhead Pharmaceuticals Stock A Smart Buy After Its Transition To A Commercial Company? (Trefis)
Jul-22-26 08:30AM	Sarepta Therapeutics to Announce Second Quarter 2026 Financial Results (Business Wire)
Jul-21-26 04:04PM	SRPT Stock Drops 4% As Citi Flags Potentially Stronger Rival In Duchenne Space (Stocktwits)
09:40AM	Shopify downgraded, Five Below upgraded: Wall Street's top analyst calls (The Fly)
Jul-13-26 09:12AM	What It Means To Hold Moderna Stock In A Crash (Trefis)
Jul-10-26 08:14AM	Beyond The Breakout Drug: Is BridgeBio Pharma Stock A Buy On Its Next Act? (Trefis) -7.65%
07:35AM	The Long Climb Back For Ionis Stock (Trefis)
Jul-09-26 07:03AM	This Analyst Sees 34% Upside For SRPT Stock Here's Why They Expect A Sustained Rally Next (Stocktwits)
Jun-30-26 04:25PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +5.58%
12:54PM	SRPT Stock Climbs After Sarepta Seeks Permanent FDA Nod For Two Duchenne Therapies (Stocktwits)
08:30AM	Sarepta Announces FDA Acceptance of sNDAs for AMONDYS 45 and VYONDYS 53 (Business Wire)
Jun-08-26 03:00AM	BioGene Therapeutics Inc. Appoints Ty Howton to Board of Directors (TMX Newsfile)
Jun-01-26 04:30PM	Sarepta Therapeutics to Participate in Upcoming Investor Conferences (Business Wire) -7.72%
May-19-26 09:33AM	Immunic appoints Biogen, Cubist veteran Mike Bonney as board chair ahead of key MS trial readout (Proactive)
May-13-26 04:30PM	Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference (Business Wire)
May-07-26 11:51AM	Sarepta tumbles as its gene therapy sales decline further (BioPharma Dive) -9.68%
10:03AM	Sarepta Dives; Can 2026 Be The Reset Year For Its Controversial Gene Therapy? (Investor's Business Daily)
08:59AM	Sarepta Stock Slumps. Why an Earnings Beat Wasn't Enough for the S&P 500 Loser. (Barrons.com)
May-06-26 06:50PM	Sarepta Stock Sinks on Earnings Beat. Elevidys Demand Faces a Reality Check. (Barrons.com) +5.69%
04:26PM	Sarepta Therapeutics: Q1 Earnings Snapshot (Associated Press)
04:05PM	Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments (Business Wire)
Apr-22-26 08:30AM	Sarepta Therapeutics to Announce First Quarter 2026 Financial Results (Business Wire)
Apr-16-26 05:58AM	Roche to start new Elevidys study following setback in Europe (BioPharma Dive)
Mar-31-26 04:05PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.25%
Mar-25-26 12:17PM	Shares of This Gene Therapy Maker Are Up 29%. The Safety Debate Is Far From Over. (Barrons.com) +34.98%
11:37AM	Sarepta Therapeutics experimental siRNA therapies show promising early results (Proactive)
10:05AM	Sarepta Surges As It Takes On Novartis' $12 Billion Muscular Dystrophy Buyout (Investor's Business Daily)
08:05AM	Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1 (Business Wire)
07:03AM	Sarepta sees early success with RNAi drugs from Arrowhead (BioPharma Dive)
Mar-24-26 04:05PM	Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1 (Business Wire)
Mar-23-26 06:16AM	FDA seeks feedback on voucher program; Study data lift overhang on Insmed shares (BioPharma Dive) +6.11%
Mar-19-26 08:30AM	Sarepta Provides Regulatory Update on AMONDYS 45 and VYONDYS 53 (Business Wire)
Mar-16-26 08:33AM	Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne (Business Wire)
05:06AM	Sarepta tests new Elevidys safeguards; Sana advances diabetes cell therapy (BioPharma Dive)
Mar-09-26 01:32PM	What's Going On With Moderna, Capricor, Other Biotech Stocks On Monday? (Benzinga) +5.57%
07:59AM	UniQure leads genetic medicine biotech rally after news of Prasads exit (BioPharma Dive)
07:01AM	Why Is uniQure Stock Skyrocketing Monday? (Benzinga)
Mar-06-26 05:56PM	FDA vaccine chief Vinay Prasad set to leave post next month (Bloomberg)
11:57AM	Can Keros Therapeutics Rinvatercept Stand Out in the DMD Market? (Zacks)
03:00AM	Biopharmas recent string of CEO splits (Pharma Voice)
Mar-01-26 04:27AM	Wells Fargo Cuts PT on Sarepta Therapeutics (SRPT) to $38 From $45 (Insider Monkey)
Feb-28-26 11:58AM	Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory (Insider Monkey)
09:30AM	Sarepta CEO To Jump Ship After 'Tumultuous' Year (Benzinga)
Feb-27-26 09:00AM	Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program (Business Wire)
Feb-26-26 10:29AM	Sarepta Q4 Loss Wider Than Expected, Sales Beat Estimates (Zacks) -8.01%
09:30AM	Compared to Estimates, Sarepta Therapeutics (SRPT) Q4 Earnings: A Look at Key Metrics (Zacks)
08:30AM	Sarepta Therapeutics to Present New Long-Term and Safety Data Across Gene Therapy and Exon-Skipping Programs at 2026 Muscular Dystrophy Association Clinical & Scientific Congress (Business Wire)
05:52AM	Sarepta CEO To Jump Ship After 'Tumultuous' Year (Benzinga)
03:08AM	Sarepta Therapeutics Q4 Earnings Call Highlights (MarketBeat)
03:00AM	Sarepta CEO Doug Ingram to retire, with company at a crossroads (BioPharma Dive)
12:05AM	Sarepta Therapeutics Inc (SRPT) Q4 2025 Earnings Call Highlights: Strong Financial Position ... (GuruFocus.com)
Feb-25-26 04:40PM	Sarepta Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments (Business Wire)
Feb-24-26 09:07AM	Sarepta Therapeutics Announces Commercial Launch of ELEVIDYS in Japan (Business Wire)
08:30AM	Sarepta Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference (Business Wire)
Feb-19-26 10:00AM	Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Feb-18-26 10:00AM	Sarepta Therapeutics (SRPT) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
09:39AM	Should Investors Buy, Sell or Hold KROS Stock Ahead of Q4 Earnings? (Zacks)
Feb-15-26 05:35AM	Solid Biosciences Highlights FDA Path for SGT-003 DMD Study, Shares Early Friedreichs Ataxia Update (MarketBeat)
Feb-11-26 08:30AM	Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results (Business Wire)
Feb-06-26 12:04AM	Arrowhead Pharmaceuticals Inc (ARWR) Q1 2026 Earnings Call Highlights: Strong Financial ... (GuruFocus.com) +8.63%
Feb-05-26 08:06PM	Arrowhead Pharmaceuticals Q1 Earnings Call Highlights (MarketBeat) -13.68%
Jan-31-26 12:02AM	Sarepta Therapeutics Touts 3-Year EMBARK Data Showing ELEVIDYS Slows DMD Decline, No New Safety Flags (MarketBeat)
Jan-27-26 10:50AM	SRPT Stock Up 8% on Positive Long-Term Data From Elevidys Study in DMD (Zacks)
06:45AM	Sarepta eyes Elevidys sales comeback with positive Phase III data (Clinical Trials Arena)
Jan-26-26 04:17PM	Sarepta Pops On Elevidys Data; But Will It Save The Embattled Gene Therapy? (Investor's Business Daily) +7.90%
02:49PM	Sarepta Stock Climbs. 3-Year Study Results for Elevidys Bring Hope. (Barrons.com)
01:26PM	Natural Gas Rallies 30%, Silver Jumps 13% To $116: What's Moving Markets Monday? (Benzinga)
12:00PM	Sarepta Therapeutics (SRPT) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Mayo Stephen	Director	Mar 12 '26	Sale	17.02	7,239	123,208	1,765	Mar 13 08:03 PM
STEPHEN MAYO	Director	Mar 12 '26	Proposed Sale	17.02	7,239	123,175		Mar 12 04:27 PM
Estepan Ian Michael	Chief Operating Officer	Feb 26 '26	Option Exercise	13.71	7,450	102,140	200,750	Mar 02 08:00 AM
Nicaise Claude	Director	Jan 29 '26	Option Exercise	13.71	10,500	143,955	38,312	Jan 29 08:05 PM
BEHRENS M KATHLEEN	Director	Jan 27 '26	Option Exercise	13.71	10,500	143,955	203,976	Jan 29 08:04 PM
Estepan Ian Michael	Chief Operating Officer	Dec 16 '25	Sale	22.31	13,187	294,202	193,300	Dec 18 08:05 PM
IAN M ESTEPAN	Officer	Dec 16 '25	Proposed Sale	22.31	13,187	294,145		Dec 16 05:05 PM

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

President & COOMr. Ian Michael Estepan

Executive VP & CFOMr. Ryan H. Wong

Executive VPMs. Cristin L. Rothfuss J.D.

J.D.Mr. Douglas S. Ingram Esq.

President of Research & Development and Technical OperationsDr. Louise R. Rodino-Klapac Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SRPT

Sarepta Therapeutics Inc

Upgrade your Finviz experience